Table 1
mAb therapy targeting cell surface antigens, cytokines, and adhesion molecules and recombinant cytokine therapy in models of immune mediated ocular inflammation and corneal allograft rejection
| Target | References | ||||
|---|---|---|---|---|---|
| Suppression | No effect/ exacerbation | ||||
| Cell surface | CD4 | 14, 42, 43, 49,50 | |||
| MHC class II | 51 | ||||
| CD8 | 52 | ||||
| Adhesion targets | ICAM-1/LFA-1 | 45, 53–57 | |||
| VLA-4 | 56,57 | ||||
| Anti-cytokine mAb | IL-12 | 46 | |||
| TNF-α | 47 | 58–60 | |||
| RHU cytokine therapy | IL-12 | 39 | |||
| IL-4 | 61 | ||||
| TNF-α | 40, 41 | ||||
-
↵These studies have shown that treatment with such mAb or recombinant cytokine suppresses target organ destruction.
-
↵These studies have shown no effect or provide evidence of paradoxical effects of therapy in some forms of experimental ocular inflammatory models although generally not experimental models of PSII.
